scholarly journals Disparities of time trends and birth cohort effects on invasive breast cancer incidence in Shanghai and Hong Kong pre- and post-menopausal women

BMC Cancer ◽  
2017 ◽  
Vol 17 (1) ◽  
Author(s):  
Feng Wang ◽  
Lap Ah Tse ◽  
Wing-cheong Chan ◽  
Carol Chi-hei Kwok ◽  
Siu-lan Leung ◽  
...  
Keyword(s):  
Breast Cancer ◽  
Hong Kong ◽  
Birth Cohort ◽  
Cancer Incidence ◽  
Invasive Breast Cancer ◽  
Time Trends ◽  
Breast Cancer Incidence ◽  
Cohort Effects ◽  
Menopausal Women ◽  
Post Menopausal

scholarly journals Historical Trends in Incidence of Breast Cancer in Shanghai, Hong Kong and Los Angeles, 1973–2012: A Joinpoint and Age-Period-Cohort Analysis

2021 ◽  
Vol 66 ◽  
Author(s):  
Hang-Hang Luan ◽  
Li-Sha Luo ◽  
Zhi-Yan Lu
Keyword(s):  
Breast Cancer ◽  
Risk Factors ◽  
Hong Kong ◽  
Los Angeles ◽  
Cancer Incidence ◽  
White Women ◽  
Cohort Analysis ◽  
Breast Cancer Incidence ◽  
Cohort Effects ◽  
Period Effect

Objectives: This study aimed to estimate the long-term trends of breast cancer incidence in Shanghai, Hong Kong, and Los Angeles (LA).Methods: Data were obtained from Cancer Incidence in Five Continents (CI5plus) database. The average annual percent change (AAPC) was conducted by joinpoint regression analysis, and the age, period and cohort effects were estimated by age-period-cohort (APC) analysis.Results: The age-standardized incidence rates (ASIRs) in LA were higher than Shanghai and Hong Kong. During 1988–2012, the ASIRs significantly decreased in white women in LA (AAPC = −0.6%, 95% CI: −0.9% to −0.4%) while increased in Shanghai (2.5%: 2.1%–2.9%) and Hong Kong (2.2%: 2.0%–2.5%). The APC analysis revealed significantly increased effects of age and period, and decreased effect of birth cohort.Conclusion: Although age and cohort effects were relatively strong, the period effect may be the key factor affecting trends of incidence, which may be caused by increasing exposures to carcinogens and risk factors. Therefore, more effective measures should be carried out promptly to protect high-risk populations such as elder women, to avoid exposures to risk factors of breast cancer.

scholarly journals Endogenous hormones and risk of invasive breast cancer in pre- and post-menopausal women: findings from the UK Biobank

2021 ◽  
Author(s):  
Sandar Tin Tin ◽  
Gillian K. Reeves ◽  
Timothy J. Key
Keyword(s):  
Breast Cancer ◽  
Breast Cancer Risk ◽  
Cancer Risk ◽  
Invasive Breast Cancer ◽  
Cox Regression ◽  
Menopausal Status ◽  
Endogenous Hormones ◽  
Uk Biobank ◽  
Menopausal Women ◽  
Post Menopausal

Abstract Background Some endogenous hormones have been associated with breast cancer risk, but the nature of these relationships is not fully understood. Methods UK Biobank was used. Hormone concentrations were measured in serum collected in 2006–2010, and in a repeat subsample (N ~ 5000) in 2012–13. Incident cancers were identified through data linkage. Cox regression models were used, and hazard ratios (HRs) corrected for regression dilution bias. Results Among 30,565 pre-menopausal and 133,294 post-menopausal women, 527 and 2,997, respectively, were diagnosed with invasive breast cancer during a median follow-up of 7.1 years. Cancer risk was positively associated with testosterone in post-menopausal women (HR per 0.5 nmol/L increment: 1.18; 95% CI: 1.14, 1.23) but not in pre-menopausal women (pheterogeneity = 0.03), and with IGF-1 (insulin-like growth factor-1) (HR per 5 nmol/L increment: 1.18; 1.02, 1.35 (pre-menopausal) and 1.07; 1.01, 1.12 (post-menopausal); pheterogeneity = 0.2), and inversely associated with SHBG (sex hormone-binding globulin) (HR per 30 nmol/L increment: 0.96; 0.79, 1.15 (pre-menopausal) and 0.89; 0.84, 0.94 (post-menopausal); pheterogeneity = 0.4). Oestradiol, assessed only in pre-menopausal women, was not associated with risk, but there were study limitations for this hormone. Conclusions This study confirms associations of testosterone, IGF-1 and SHBG with breast cancer risk, with heterogeneity by menopausal status for testosterone.

scholarly journals Trends in breast cancer incidence in Sweden 1958-1988 by time period and birth cohort

1993 ◽  
Vol 68 (6) ◽  
pp. 1247-1253 ◽  
Author(s):  
I Persson ◽  
R Bergström ◽  
P Sparén ◽  
M Thörn ◽  
H-O Adami
Keyword(s):  
Breast Cancer ◽  
Birth Cohort ◽  
Cancer Incidence ◽  
Breast Cancer Incidence ◽  
Time Period

Metformin and breast cancer risk: A meta-analysis and critical literature review.

2012 ◽  
Vol 30 (27_suppl) ◽  
pp. 25-25
Author(s):  
Nananda Col ◽  
Leslie Ochs ◽  
Vicky Springmann ◽  
Aaron K Aragaki ◽  
Rowan T. Chlebowski
Keyword(s):  
Breast Cancer ◽  
Breast Cancer Risk ◽  
Cancer Risk ◽  
Literature Review ◽  
Cancer Incidence ◽  
Invasive Breast Cancer ◽  
Meta Analysis ◽  
Breast Cancer Incidence ◽  
Cochrane Library ◽  
Study Quality

25 Background: Observational studies have suggested that metformin, commonly used for diabetes treatment that increases insulin sensitivity and improves glycemic control, decreases the incidence of several common cancers. However, findings regarding metformin and breast cancer incidence have been mixed. To explore this issue, a systematic literature review and meta-analysis were performed with a focus on potential biases. Methods: We conducted a comprehensive literature search for all pertinent studies addressing metformin use and breast cancer risk by searching Pub Med, Cochrane Library, Scopus (which includes Embase, ISI Web of Science) using the Mesh terms: "metformin" or "biguanides" or "diabetes mellitus, type 2/therapy" and "cancer" or "neoplasms". When multiple hazard ratios (HR) or odds ratio (OR) were reported, the most adjusted estimate was used in the base-case analysis. We pooled the adjusted HR using and performed sensitivity analyses on duration of metformin use (> or < 3 years use), study quality (assessed using the GRADE system), and initial observation year of the cohort (before vs after 1997). Results: From a total of 421 citations, 13 full-text articles were considered, and 7 independent studies were included. All were observational (4 cohort and 3 case control). Our combined OR for metformin association with invasive breast cancer of all 7 studies was 0.83 (95% CI, 0.71-0.97). Funnel plot analyses did not suggest publication bias. Stronger associations were found when analyses were limited to studies estimating the impact of longer metformin duration (OR = 0.75. 95% CI, 0.62-0.91) or among studies that began observing their cohort before 1997 (OR=0.68. 95% CI, 0.55-0.84). Stratification according to study quality did not affect the combined OR but higher quality studies had smaller CI and achieved statistical significance. Interpretation is limited by the observational nature of reports and different comparison groups. Conclusions: Our analyses support a protective effect of metformin on invasive breast cancer incidence among postmenopausal women with diabetes. Clinical trials are needed to determine whether metformin reduces breast cancer risk.

Absence of sustained breast cancer incidence inflation in a national mammography screening programme

2018 ◽  
Vol 26 (1) ◽  
pp. 26-34 ◽  
Author(s):  
Stephen Morrell ◽  
Marli Gregory ◽  
Kerry Sexton ◽  
Jessica Wharton ◽  
Nisha Sharma ◽  
...  
Keyword(s):  
Breast Cancer ◽  
New Zealand ◽  
Cancer Incidence ◽  
Invasive Breast Cancer ◽  
Mammography Screening ◽  
Screening Programme ◽  
Breast Cancer Incidence ◽  
Age Groups ◽  
Incidence Trends ◽  
The Impact

Objective To investigate the impact of population mammography screening on breast cancer incidence trends in New Zealand. Methods Trends in age-specific rates of invasive breast cancer incidence (1994–2014) were assessed in relation to screening in women aged 50–64 from 1999 and 45–69 following the programme age extension in mid-2004. Results Breast cancer incidence increased significantly by 18% in women aged 50–64 compared with 1994–98 (p<0.0001), coinciding with the 1999 introduction of mammography screening, and remained elevated for four years, before declining to pre-screening levels. Increases over 1994–99 incidence occurred in the 45–49 (21%) and 65–69 (19%) age groups following the 2004 age extension (p<0.0001). Following establishment of screening (2006–10), elevated incidence in the screening target age groups was compensated for by lower incidence in the post-screening ⩾70 age groups than in 1994–98. Incidence in women aged ⩾45 was not significantly higher (+5%) after 2006 than in 1994–98. The cumulated risk of breast cancer in women aged 45–84 for 1994–98 was 10.7% compared with 10.8% in 2006–10. Conclusions Increases in breast cancer incidence following introduction of mammography screening in women aged 50–64 did not persist. Incidence inflation also occurred after introduction of screening for age groups 45–49 and 65–69. The cumulated incidence for women aged 45–84 over 2006–10 after screening was well established, compared with 1994–98 prior to screening, shows no increase in diagnosis. Over-diagnosis is not inevitable in population mammography screening programmes.

Sign in / Sign up

Export Citation Format

Share Document